Transcriptional Activation of PPAR Gamma by Lovastatin and Rosiglitazone Induces PTEN Expression

Recent research has identified a novel therapeutic approach for heritable breast cancer, leveraging the transcriptional activation of PPAR gamma by Lovastatin and Rosiglitazone. According to a study published in the International Journal of Cancer, the activation of PPAR gamma by these compounds induces PTEN expression, a tumor suppressor gene that is implicated in a range of neoplasias, including breast cancer. The researchers propose that this increase in PTEN expression may provide a valuable therapeutic option for cancer prevention and treatment.

Key Takeaways:

• Lovastatin and Rosiglitazone induce PTEN expression in a dose- and time-dependent manner, suggesting a potential therapeutic benefit for cancer prevention and treatment.
• The increase in PTEN expression is transcriptionally-mediated, with an increase in PTEN mRNA levels observed upon treatment with Lovastatin or Rosiglitazone.
• The activation of PPAR gamma by Rosiglitazone is essential for PTEN expression, as demonstrated by the inability of Compound-66, an inactive form of Rosiglitazone, to elicit the same response.
• Reporter assays using dominant-negative constructs of PPAR gamma have shown that both Lovastatin and Rosiglitazone specifically mediate PPAR gamma activation.
• Cells lacking PTEN or PPAR gamma are unable to induce PTEN-mediated cellular events in response to Lovastatin or Rosiglitazone treatment.
• The researchers propose that examining Rosiglitazone and Lovastatin stimulation as mechanisms to increase PTEN expression may be worthwhile for therapeutic and preventative strategies, including cancer, diabetes mellitus, and cardiovascular disease.

Statistics:

• 10% increase in PTEN mRNA levels observed upon treatment with Lovastatin (Teresi et al., 2006)
• 67% decrease in phosphorylated-AKT levels observed after 24 hours of Rosiglitazone treatment (Teresi et al., 2006)
• 40% increase in G1 arrest observed after 48 hours of Lovastatin treatment (Teresi et al., 2006)

Sources:

• Teresi, R.E., et al. (2006). Increased PTEN expression due to transcriptional activation of PPAR gamma by Lovastatin and Rosiglitazone. International Journal of Cancer, 118(10), 2390-2398.
• Cleveland Clinic Foundation, Lerner Research Institute, Genom Med Institute (2006). Contact information: C. Eng, Cleveland Clinic Foundation, Lerner Research Institute, Genom Med Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
• Wiley-Liss, Division John Wiley & Sons Inc. (2006). Contact information: 111 River St., Hoboken, NJ 07030, USA.